Unichem Laboratories receives US FDA approval for migraine drug

It has received approval for rizatriptan benzoate ODT & rizatriptan benzoate tablets

Premium

BS B2B Bureau Mumbai

Last Updated : Mar 08 2017 | 5:27 PM IST

Unichem Laboratories Limited has received ANDA approval from the US Food and Drug Administration (FDA) for rizatriptan benzoate ODT 5 mg & 10 mg and rizatriptan benzoate tablets 5 mg & 10 mg. Rizatriptan benzoate ODT and rizatriptan benzoate tablets are therapeutically equivalent to Merck & Co’s Maxalt MLT tablets and Maxalt tablets, respectively.

Rizatriptan benzoate is a serotonin (5-HT) 1B/1D receptor agonist (triptan) indicated for the acute treatment of migraine in adults and in paediatric patients 6 to 17 years of age.

The product will be commercialised from Unichem’s Goa plant. Active pharmaceutical ingredient (API) will also be made in house

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in